Different proportions of various prostate-specific antigen (PSA) and human kallikrein 2 (hK2)forms are present in noninduced and androgen-induced LNCaP cells

Prostate

Volumn 44, Issue 3, 2000, Pages 248-254

  Kumar, Abhay ^a   Mikolajczyk, Stephen D ^a   Hill, Timothy M ^a   Millar, Lisa S ^a   Saedi, Mohammad S ^a  

^a Hybritech Incorporated   (United States)

Author keywords

Androgen; Biosynthesis; HK2; Human kallikreins; Prostate cancer; PSA

Indexed keywords

ANDROGEN; KALLIKREIN; MIBOLERONE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER;

ALPHA 1-ANTICHYMOTRYPSIN; ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NANDROLONE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; SEQUENCE ANALYSIS, PROTEIN; TESTOSTERONE CONGENERS; TISSUE KALLIKREINS; TUMOR CELLS, CULTURED;

EID: 0034255645     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20000801)44:3<248::AID-PROS10>3.0.CO;2-D     Document Type: Article

References (31)

1. Horoszewicz J, Leong S, Chu T, Wajsman Z, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA. The LNCaP cell line: a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980;37:115-132.
2. Lilja H. Prostate-specific antigen: molecular forms and the human kallikrein gene family. Br J Urol [Suppl] 1997;79:44-48.
3. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998;35:275-368.
4. Watt KWK, Lee P-J, M'TimKulu T, Chan W-P, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986;83:3166-3170.
5. Ban Y, Wang MC, Watt KWK, Loor R, Chu TM. The proteolytic activity of human prostate-specific antigen. Biochem Biophys Res Commun 1984;123:482-488.
6. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985;76:1899-1903.
7. Cohen P, Graves HCB, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75:1046-1053.
8. Saedi MS, Mikolajczyk SD, Kumar A. Kallikreins. In: Creighton T, editor. Encyclopedia of molecular biology. New York: John Wiley and Sons; 1999. p 1335-1339.
9. Fukushima D, Kitamura N, Nakanishi S. Nucleotide sequence of cloned cDNA for human pancreatic kallikrein. Biochemistry 1985;24:8037-8043.
10. Morris BJ. hGK-1: a kallikrein gene expressed in human prostate. Clin Exp Pharmacol Physiol 1989;16:345-351.
11. Young CYF, Andrews PE, Tindall DJ. Expression and androgenic regulation of human prostate-specific kallikreins. J Androl 1995;16:97-99.
12. Mikolajczyk SD, Millar LS, Kumar A, Saedi MS. Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. Prostate 1998; 34:44-50.
13. Deperthes D, Frenette G, Brillard-Bourdet M, Bourgois L, Gauthier F, Tremblay R, Dube JY. Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. J Androl 1996;17:659-665.
14. Kumar A, Mikolajczyk SD, Goel AS, Millar LS, Saedi MS. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997;57:3111-3114.
15. Mikolajczyk SD, Millar LS, Marker KM, Grauer LS, Goel AS, Cass MMJ, Kumar A, Saedi MS. Alanine 217 is important for the catalytic function and autoactivation of prostate-specific human kallikrein 2. Eur J Biochem 1997;246:440-446.
16. Frenette G, Tremblay RR, Lazure C, Dube JY. Prostatic kallkrein (hK2), but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int J Cancer 1997; 71:897-899.
17. Mikolajczyk SD, Millar LS, Kumar A, Saedi MS. Prostatic human kallikrein 2 inactivates and complexes with plasminogen activator inhibitor-1. Int J Cancer 1999;81:438-442.
18. Mikolajczyk SD, Millar LS, Wang TJ, Wolfert RL, Rittenhouse HR, Marks LS, Song W, Wheeler TM, Slawin KM. "B-PSA," a specific molecular form of free prostate specific antigen, is found predominantly in the transition zone of patients with nodular BPH. Urology 2000;55:41-45.
19. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-1220.
20. Saedi MS, Hill TM, Kuus-Reichel K, Kumar A, Payne J, Mikolajczyk SD, Wolfert RL, Rittenhouse HG. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. Clin Chem 1998;44:2115-2119.
21. Finlay JA, Evans CL, Day JR, Payne JK, Mikolajczyk SD, Millar LS, Kuus-Reichel K, Wolfert RL, Rittenhouse HG. Development of monoclonal antibodies specific for human glandular kallikrein (hK2):development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology 1998;51:804-809.
22. Kumar A, Goel AS, Hill TM, Mikolajczyk SD, Millar LS, Kuus-Reichel K, Saedi MS. Expression of human glandular kallikrein, hK2, in mammalian cells. Cancer Res 1996;56:5397-5402.
23. Corey E, Brown LG, Corey MJ, Buhler KR, Vessella RL. LNCaP produces both putative zymogen and inactive, free form of prostate-specific antigen. Prostate 1998;35:135-143.
24. Herrala A, Kurkela R, Vihinen M, Kalkkinen N, Vihko P. Androgen-sensitive human prostate cancer cells, LNCaP, produce both N-terminally mature and truncated prostate-specific antigen isoforms. Eur J Biochem 1998;255:329-335.
25. Heuze N, Olayat S, Gutman N, Zani ML, Courty Y. Molecular cloning and expression of an alternative hKLK3 transcript coding for a variant protein of prostate-specific antigen. Cancer Res 1999;59:2820-2824.
26. Mikolajczyk SD, Millar LS, Marker KM, Rittenhouse HG, Wolfert RL, Marks LS, Charlesworth MC, Tindall DJ. Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue. Cancer Res 1999;59:3927-3930.
27. Diamandis EP. Prostate-specific antigen - its usefulness in clinical medicine. Trends Endocrinol Metab 1998;9:310-316.
28. Black MH, Magklara A, Obiezu C, Levesque MA, Sutherland DJ, Tindall DJ, Young CY, Sauter ER, Diamandis EP. Expression of a prostate associated protein, human glandular kallikrein (hK2) in breast tumors and in normal breast secretions. Br J Cancer 2000;82:361-367.
29. Zarghami N, Grass L, Diamandis EP. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer 1997;75:579-588.
30. Hsieh ML, Charlesworth MC, Goodmanson M, Zhang S, Seay T, Klee GG, Tindall DJ, Young CY. Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D. Cancer Res 1997;57:2651-2656.
31. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJ, Levesque MA, Roagna R, Ponzone R, Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 1995;55:2104-2110.